Enclomiphene is an oral selective estrogen receptor modulator, or SERM, that can stimulate a man's own testosterone production by increasing signals from the brain to the testes. Unlike testosterone replacement therapy, it does not provide testosterone directly from outside the body.
That single distinction, stimulating your own production versus replacing it, is the key to understanding everything else about enclomiphene. But two things have to be said right up front, because a lot of men's-health marketing skips them.
First, enclomiphene is not an FDA-approved medication in the United States. It has been studied for men with secondary hypogonadism and is available in some settings as a compounded medication, but its evidence and regulatory status are different from FDA-approved testosterone products. Second, stimulating your own production does not automatically make enclomiphene a "safer" or "more natural" version of TRT. It works through a different mechanism, is appropriate only for certain forms of low testosterone, and has less long-term clinical evidence than testosterone therapy. Its most interesting potential advantage is that it can raise testosterone while maintaining LH and FSH signaling, which is what makes it worth discussing when preserving fertility matters.
Enclomiphene at a glance
- What is it? An oral selective estrogen receptor modulator (SERM)
- Is it testosterone? No
- Is it a steroid? No
- Is it a peptide? No
- What does it do? Raises LH and FSH signaling, which can increase the testes' own testosterone production
- Why might a man use it? Certain forms of secondary or functional low testosterone, especially when preserving testicular function or fertility matters
- Fertility? Much less suppressive to sperm production than exogenous testosterone
- FDA approved? No
How does enclomiphene work?
To understand enclomiphene, it helps to see the normal signaling loop that controls testosterone, the hypothalamic-pituitary-gonadal (HPG) axis:
Brain (GnRH) → pituitary (LH + FSH) → testes → testosterone + sperm
Estrogen normally provides negative feedback to the hypothalamus and pituitary, telling them to ease off. Enclomiphene blocks some of that estrogen feedback at the brain, which allows LH and FSH signaling to increase.
LH tells the testes to make testosterone
Luteinizing hormone (LH) stimulates the Leydig cells in the testes to produce testosterone.
FSH supports sperm production
Follicle-stimulating hormone (FSH) supports spermatogenesis, which is central to why enclomiphene behaves so differently from testosterone therapy.
So the simplest way to put it: enclomiphene turns up the body's own signaling system rather than replacing testosterone from outside it. Pooled randomized data support increases in testosterone, LH and FSH with SERM therapy.
What kind of low testosterone can enclomiphene help?
This is the part that matters most, and it is where honest content separates itself from marketing. Enclomiphene is conceptually aimed at secondary (or functional) hypogonadism, where the testes still have the ability to respond to stimulation.
Secondary hypogonadism
Testosterone is low while LH and FSH are low or inappropriately normal, meaning the hypothalamic-pituitary signal is insufficient relative to the testosterone level, while the testes retain enough function to potentially respond. Possible associations include obesity, metabolic dysfunction, certain medications, hypothalamic or pituitary signaling issues, and other reversible or functional causes.
Primary hypogonadism
Here the testicular function itself is impaired, often with elevated LH and FSH as the body tries and fails to compensate.
The key idea: if the testes cannot adequately respond to LH and FSH, simply increasing those signals may not solve the problem. That is exactly why an actual workup matters, you need to know why testosterone is low before deciding whether a medication that boosts signaling even makes biological sense. This is covered in how to test your testosterone.
Does enclomiphene work? What the evidence shows
Yes, in appropriately selected men it can, and the evidence on that specific point is fairly strong. A 2025 systematic review and meta-analysis of randomized trials involving clomiphene and enclomiphene (10 trials, 819 patients) found that SERM therapy significantly increased total testosterone, LH and FSH versus placebo, with total testosterone increases that were not significantly different from testosterone gel in pooled comparisons. Even so, the included studies were short (roughly 2 to 30 weeks), and the authors noted the pooled evidence was underpowered for safety endpoints and mostly reported hormone numbers rather than symptom outcomes.
Here is the crucial caveat: raising the testosterone number is not the same thing as proving a man will feel better. Older enclomiphene trials were much stronger on hormone endpoints than on validated symptom or quality-of-life outcomes, and the FDA specifically cited a lack of demonstrated clinical benefit when it declined to approve the drug. So the honest summary is: it has consistently increased testosterone in randomized trials of appropriately selected men with secondary hypogonadism, but whether a higher number translates into better energy, libido, mood or body composition varies by patient and is less well established in long-term trials.
Enclomiphene vs TRT: what's the difference?
This is the comparison most people come for. The clearest way to see it:
| Feature | Enclomiphene | Testosterone therapy (TRT) |
|---|---|---|
| Provides testosterone directly | No | Yes |
| Stimulates body's own production | Yes | No |
| LH / FSH | Generally maintained or increased | Usually suppressed |
| Sperm production | Often better preserved | Can be substantially suppressed |
| Administration | Oral | Injection, gel, other FDA-approved forms |
| FDA-approved for male hypogonadism | No | Yes, for appropriate diagnosed hypogonadism |
| Long-term evidence | More limited | Much larger evidence base |
Two things this table should not be read to say. TRT is not "bad" because it suppresses LH and FSH, that is simply how exogenous testosterone changes the HPG axis. And enclomiphene is not automatically better because it maintains signaling. They are different tools for different patients.
Does enclomiphene preserve fertility?
Fertility preservation is one of the main clinical reasons enclomiphene is considered, and the evidence here is promising and fairly consistent. In an early randomized study, testosterone rose with both enclomiphene and topical testosterone, but sperm concentrations were preserved with enclomiphene while they fell substantially with exogenous testosterone. More recent pooled randomized data also support preservation of gonadotropins and better preservation of sperm concentration than exogenous testosterone in the studied populations.
The careful way to state it: enclomiphene may be particularly useful when a man has secondary hypogonadism and fertility preservation is an important goal. It does not guarantee fertility, and if fertility is an active concern, a semen analysis and appropriate fertility evaluation can still matter.
Does TRT really lower sperm count?
Yes, and understanding why makes the enclomiphene mechanism tangible. Exogenous testosterone suppresses LH and FSH. Reduced LH signaling can lower the testosterone produced inside the testes, and sperm production can fall substantially; testicular volume can also decrease in some men. That is why exogenous testosterone is generally avoided as sole therapy when near-term fertility is a priority, and why a medication that preserves LH and FSH signaling is attractive in that specific situation.
Enclomiphene vs Clomid (clomiphene)
People often use these names interchangeably, and they are related but not identical. Clomiphene citrate (Clomid) contains two isomers: enclomiphene and zuclomiphene. Enclomiphene is essentially the trans isomer isolated from that mixture. Older mechanistic literature suggests enclomiphene is responsible for much of the gonadotropin-stimulating effect, while zuclomiphene has different estrogenic activity and stays in the body much longer.
It is tempting to conclude enclomiphene therefore has fewer mood, visual or estrogenic side effects than Clomid, but that is not established. There are pharmacologic reasons enclomiphene may behave differently, but high-quality head-to-head clinical evidence showing a large safety or symptom advantage remains limited. A 2026 British Society for Sexual Medicine position statement acknowledges a potential role but cautions that the evidence base is small and short-term, and it does not recommend routine use outside specialist settings.
Is enclomiphene FDA-approved?
No, and this deserves a clear explanation, because the search results on this are genuinely confusing.
Enclomiphene was developed as Androxal for secondary hypogonadism and went through Phase III development, but the FDA did not approve it. A central issue was that raising testosterone levels alone did not establish a meaningful clinical benefit for treating hypogonadism. Later, when a compounding pharmacy nominated enclomiphene citrate for the 503A compounding bulks list, the FDA's Pharmacy Compounding Advisory Committee voted 8 to 4 against including it in 2022, with members citing the lack of demonstrated clinically meaningful benefit despite increases in testosterone and gonadotropins.
There is one nuance worth stating precisely. The 2022 committee vote was advisory. As of FDA's May 2026 update, enclomiphene citrate nevertheless remains a "Category 1" bulk substance under evaluation for Section 503A compounding while FDA evaluation remains ongoing. Category 1 is an interim regulatory status; it does not mean enclomiphene is FDA-approved or that it has been added to the final 503A Bulks List. Compounded enclomiphene products are therefore different from FDA-approved drug products.
Important: enclomiphene is not FDA-approved. It has been studied in men with secondary hypogonadism but has never received FDA approval as a testosterone treatment. A compounded enclomiphene prescription is not the same thing as receiving an FDA-approved enclomiphene product, because no such U.S. product currently exists.
If enclomiphene isn't FDA-approved, why do providers use it?
Because the picture is more nuanced than "approved or worthless." Providers consider it for several real reasons: promising hormone data, its preservation of LH and FSH, fertility considerations, dissatisfaction with the fertility-suppressing effects of TRT, long clinical experience with the related drug clomiphene, and renewed specialist interest. A 2026 British Society for Sexual Medicine position statement acknowledged a potential role for enclomiphene, particularly where fertility preservation matters, but also emphasized that the evidence comes from small, short-term studies with limited long-term safety data, and it does not recommend routine use outside specialist settings.
But professional interest is not the same as FDA approval, and the evidence base remains smaller than it is for established testosterone therapies. Both of those things are true at once, which is exactly why it belongs in a careful, provider-led conversation rather than a self-prescribed protocol.
What are the potential benefits of enclomiphene?
Worth framing as potential, not promised:
- Hormonal: higher endogenous testosterone, higher LH and FSH, preserved HPG-axis signaling.
- Fertility-related: less suppression of sperm production than exogenous testosterone.
- Practical: it is an oral medication, with no testosterone injections or gels.
- Possible symptom improvements: some men may notice changes in libido, energy, sexual function, mood or recovery.
The qualifier matters and bears repeating: the evidence that enclomiphene raises laboratory testosterone is stronger than the evidence that it consistently improves specific symptoms or body composition.
What are the side effects and risks of enclomiphene?
Potential concerns reported or considered with SERM and enclomiphene use include headache, nausea, mood changes, increased estradiol, changes in libido, possible visual symptoms, changes in some lab parameters, and uncertain long-term safety. Two of these deserve a closer, honest look.
Visual symptoms
Visual side effects are well recognized with clomiphene. The precise frequency and long-term visual risk with enclomiphene alone are less certain because the clinical experience is smaller, notably, its Phase III program included formal ophthalmic monitoring, indicating that visual safety was an area of active assessment during development. The responsible statement is not "enclomiphene can't cause eye problems," it is that any new visual symptom is worth reporting to your provider promptly.
Blood clots
SERMs as a class raise concern for clotting events in certain settings, but enclomiphene-specific incidence in men is not well established. Personal and family clotting history should be part of a provider's risk assessment.
Can enclomiphene raise estrogen?
Yes, potentially, and this corrects a common myth. If testosterone production rises, some of it can convert (aromatize) into estradiol. The 2025 SERM meta-analysis actually found estradiol increased versus placebo. So enclomiphene does not simply "block estrogen everywhere," and taking it does not guarantee low estradiol. It also is not a reason to automatically add an aromatase inhibitor, that is a provider decision based on real labs and symptoms, not a default add-on.
Does enclomiphene cause hair loss or build muscle?
On hair: direct evidence linking enclomiphene itself to male-pattern hair loss is limited. Because treatment can increase testosterone and downstream androgen exposure, men already predisposed to androgenetic alopecia could theoretically notice progression.
On muscle: enclomiphene is not approved or intended as a bodybuilding drug. If it moves testosterone from a genuinely low level into a healthier range, that may indirectly affect body composition, recovery or training response. It is not a bodybuilding or performance-enhancement treatment and should not be used simply to push testosterone into supraphysiologic ranges.
Is enclomiphene a steroid or a peptide?
Neither. Enclomiphene is a small-molecule selective estrogen receptor modulator (SERM). It is not a steroid, not an anabolic steroid, and not a peptide. If you are researching peptides separately, see peptides for weight loss, which is a completely different category.
How long does enclomiphene take to work?
It is worth separating two different clocks. Laboratory response: hormone changes can occur within weeks in clinical studies. Symptom response: there is no guaranteed timeline, because symptoms may not actually be testosterone-driven, raising the number does not guarantee symptom improvement, and different patients respond differently. In practice, bloodwork may change before a person can tell whether their symptoms have improved.
What happens if you stop enclomiphene?
Enclomiphene's testosterone-raising effect is not expected to be permanent once treatment stops. After it is discontinued, LH, FSH and testosterone may move back toward your untreated baseline, depending on the underlying cause of the low testosterone and whether that cause has changed. That last point is important: if someone lost weight, treated sleep apnea, stopped a suppressive medication or improved their metabolic health, their baseline might not be identical later. The only way to know is follow-up assessment and labs.
Who might be a candidate for enclomiphene?
Possible considerations a provider weighs include symptoms compatible with testosterone deficiency, repeatedly low morning testosterone, evidence pointing to secondary rather than primary hypogonadism, testes capable of responding to LH and FSH, a desire to preserve fertility or testicular signaling, and a preference to avoid exogenous testosterone after an informed discussion. Reversible causes of low testosterone (such as weight, sleep apnea, certain medications, or metabolic health) should be addressed where possible before or alongside drug therapy. And just as important: a normal or borderline testosterone number by itself is not a reason to take enclomiphene.
What labs matter with enclomiphene?
This is where a real evaluation earns its keep. Depending on the situation, a provider may look at early-morning total testosterone (repeated when appropriate), LH, FSH, SHBG, free testosterone when indicated, estradiol in the right context, and other safety labs, plus a semen analysis if fertility is a key goal. The most important of these are LH and FSH, because they help determine whether stimulating the axis even makes biological sense in the first place. You can read more about the testing side in how to test your testosterone and hormone blood testing.
What should you expect before and after enclomiphene?
Before treatment, the important question is whether the low-testosterone pattern is actually one that can respond to increased LH and FSH signaling, in other words, secondary hypogonadism with testes able to respond. After treatment starts, the most useful measures are repeat testosterone, LH and FSH where relevant, symptoms, safety labs, and fertility goals if they apply. The honest bottom line for the common "enclomiphene before and after" search: a higher testosterone number by itself is not a successful "after" result if symptoms do not improve, which is exactly why the evaluation looks at more than one lab value.